Qubigen's mission is to accelerate drug discovery through enhanced, secure AI Engines powered by our patented Federated AI platform, enabling breakthroughs against the world's toughest diseases that no single company can achieve alone.
Contact
Objectives
- Seeking 3-5 strategic partnerships with leading chemistry/early drug discovery CROs and mid-sized biopharma companies for Qubigen’s Federated AI platform
- Particularly interested in CROs looking to differentiate with proprietary, privacy-first AI tools that deliver measurable margin uplift (2.5–3x)
- Focus areas include hit-to-lead optimisation, ADMET prediction, virtual screening and client-specific, retrosynthesis AI, tox/safety screening
- Seeking conversations with Series A investors who value named CRO traction and validated case studies
News
New case study
Patented Federated AI delivered a 35% accuracy uplift on real client-specific blood-brain-barrier (BBB) permeability data versus the leading public benchmark (Greenstone/Stanford model)
Real-World Collaborations Driving Breakthrough Therapies
Multiple signed projects with Dana-Farber Cancer Institute, Mayo clinic, and world-leading Australian universities (project pipeline: 20+ institutes)